Table 1.
Number of patients | 56 |
Age (yr) | 51 ± 131 |
Sex M : F (%) | 29 : 71 |
BMI (kg/m2) | 30.8 ± 7.6 |
History of liver disease (%) | 8.9 |
Bosentan exposure (g/m2) | 611 ± 677 |
CYP2C9 inhibitors (%) | 5.3 |
CYP3A4 inhibitors (%) | 8.9 |
MRP2 inhibitors (%) | 3.6 |
BSEP inhibitors (%) | 0 |
OATP1B1 inhibitors (%) | 57.1 |
OATP1B3 inhibitors (%) | 0 |
Data is presented as either mean ± S.D. or percent of total group.